Last Thursday, we had the pleasure of officially launching AtheroNeth with our kick-off meeting! This marked the beginning of an exciting collaboration between top researchers of the Netherlands.
AtheroNeth is a national Dutch research consortium, sponsored by the Hartstichting that encompasses top research groups from all Dutch University Medical Centers.
Aim of AtheroNeth is to improve treatment of patients with ASCVD by deciphering distinct molecular phenotypes & developing innovative modalities based on multidimensional data sources that will improve patient stratification and lead to personalized therapy choices.
Thursday was a day filled with discussions and shared ambitions. We’re very excited to work together towards innovative solutions and impactful science.
A big thank you to everyone who participated and contributed to this successful start. We’re looking forward to what lies ahead!
